Contact

Lowering Drug Prices in the US-Look Within, Not Abroad

Gondi S, Papanicolas I, Rome BN - JAMA

  • Commentary & Opinion
| September 2025
  • Price, Value, and Access

Summary:

The authors outline the limitations of benchmarking US drug prices to those abroad via international reference pricing, recommending instead that the US adopt transparent, evidence-based health technology assessment and negotiation processes to address high drug costs.

VIEW SOURCE
Talk bubble graphics representing commentary and opinion.

LEARN MORE

BROWSE COMMENTARY & OPINION

Recent Work from PORTAL

Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing

Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics

  • Research Publications
| November 2026
  • Price, Value, and Access
View Source
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Coverage and Costs for Medications After Medicare Price Negotiation

Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine

  • Research Publications
| October 2026
  • Price, Value, and Access
View Source
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty

Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open

  • Research Publications
| October 2026
  • Price, Value, and Access
View Source
VIEW MORE

Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115

©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.